Statistical analysis:
We compared the baseline characteristics between subjects who had a history of use of ACEI/ARB those who didn’t use these medications using the chi-square test and t-test (Table1). First, we performed a simple logistic regression analysis to study the association between ICU admission rates and the use of ACEI/ARBs. We then used a multivariate logistic regression model to adjust for possible confounders including age, sex, race, BMI, COPD, asthma, use of aldosterone antagonists, heart failure, DM, and ESRD. Using the same methods, we studied the association between COVID-19 mortality and the use of ACEI/ARB. We used a Cox proportional hazards model to study the association between the use of ACEI/ARB and 30 days-COVID-19 survival. We censored the time to the event to 30 days. We first performed a univariate model and then performed a multivariate-adjusted model. We adjusted for the same possible confounders as those mentioned above.
R studio was used to analyze the data and a p-value of ≤0.05 was considered statistically significant.